Silvia Díaz Fernández (Silvia Díaz-Fernández)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Randomized Controlled Trial

Prognostic Factors

Bipolar Disorder

Top Venues

Journal of clinical medicine

Neuropsychiatric disease and treatment

Archives of women's mental health

This page only lists publications with an associated author ORCID identifier.

Publications

Juan José Fernández-Miranda, Silvia Díaz Fernández
Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety. Neuropsychiatric disease and treatment 19 (2023)
Silvia Díaz Fernández, Juan José Fernandez Miranda, Francisco Pascual Pastor, Francisco López Muñoz
Gender and addiction and other mental disorders comorbidity: sociodemographic, clinical, and treatment differences. Archives of women's mental health (2023)
Juan José Fernández-Miranda, Silvia Díaz Fernández, Francisco López Muñoz
The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage-A 5-Year Follow-Up. Biomedicines 11 (1) (2022)
Juan José Fernández-Miranda, Silvia Díaz Fernández, Francisco López Muñoz
The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage-A 5-Year Follow-Up. Biomedicines 11 (1) (2022)
Juan José Fernández-Miranda, Silvia Díaz Fernández, Francisco López Muñoz
The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage-A 5-Year Follow-Up. Biomedicines 11 (1) (2022)
Juan José Fernández-Miranda, Silvia Díaz Fernández, Domenico de Berardis, Francisco López Muñoz
Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia. Journal of clinical medicine 10 (7) (2021)